The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지

The Effect of Antibiotic Resistance on the Eradication of Helicobacter pylori

Helicobacter pylori 제균에 미치는 항생제 내성효과

김나영

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186
  2. NIH consensus conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65- 69
  3. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12 https://doi.org/10.1111/j.1440-1746.1998.tb00537.x
  4. Malfertheiner P, Megraud F, O' Morain C, et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180
  5. Huang JQ, Hunt RH. Treatment after failure: the problem of 'non-responders'. Gut 1999;45(suppl 1):40S-44S
  6. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999;13:857-864
  7. Perri F, Qasim A, Marras L, O' Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003;8:53-60
  8. Kim JM, Kim JS, Jung HC, Kim N, Song IS. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean J Gastroenterol 2004;44:126-135
  9. Midolo PD, Lambert JR, Turnidge J. Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. J Gastroenterol Hepatol 1996;11: 290-292
  10. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systemic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047- 1055
  11. Lerang F, Moum B, Ragnhildstveit E, et al. Simplified 10 day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance. Am J Gastroenterol 1998;93:212-216
  12. Kim N, Lim CN, Lim SH, et al. Establishment of an Helicobacter pylori-eradication regimen in consideration of drug resistance, recrudescence and reinfection of H. pylori. Korean J Med 1999;56:279-291
  13. Battaglia G, Di Mario F, Vigneri S, et al. Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series. Ital J Gastroenterol Hepatol 1998;30:370-374
  14. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999;57:905-920
  15. Deltenre M, Ntounda R, Jonas C, De Koster E. Eradication of Helicobacter pylori: why does it fail? Ital J Gastroenterol Hepatol 1998;30(suppl 3):326S-328S
  16. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272- 1277
  17. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000;320:31-34
  18. Axon AT. Treatment of Helicobacter pylori: an overview. Aliment Pharmacol Ther 2000;14(suppl 3):1S-6S
  19. Peitz U, Sulliga M, Wolle K, et al. High rate of posttherapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-324
  20. Korean Helicobacter pylori Study Group. Diagnosis and treatment for Helicobacter pylori infection in Korea. Korean J Gastroenterol 1998;32:275-289
  21. Gisbert JP, Boixeda D, Bermejo F, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999;11:1049-1054
  22. Elizalde IR, Borda F, Jara C, Martinez A, Rodriguez C, Jimenez J. Efficiency of two consecutive treatments in the eradication of Helicobacter pylori (in Spanish). Med Clin (Barc) 2000;114:185-195
  23. Gomollon F, Ducons JA, Ferrero M, et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999;4:222-225
  24. Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260-263
  25. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999;13:489-496
  26. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311- 1316
  27. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62
  28. Sicilia B, Sierra E, Lago A, Villar M, Garcia S, Gomollon F. High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy (in Spanish). Med Clin (Barc) 2000;115: 641-643
  29. Baena JM, Lopez C, Rams F, Garcia M, Rosario M, Teruel J. Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin (in Spanish). Med Clin (Barc) 2000;115:617-619
  30. Michopoulos S, Tsibouris P, Bouzakis H, et al. Randomised study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000; 14:737-744
  31. Park MJ, Choi IL, Kim JS, et al. Efficacy of quadruple therapy as retreatment regimen in Helicobacter pyloripositive peptic ulcer disease. Korean J Gastroenterol 2000; 36:457-464
  32. Lee JY, Kim W, Gawk GY, et al. Reinfection rate and clinical manifestation of Helicobacter pylori-positive peptic ulcer disease after triple therapy containing clarithromycin. Korean J Gastroenterol 2002;39:93-100
  33. Chung WC, Cho YS, Jeong JJ, et al. Eradication rate of Helicobacter pylori according to the diseases and therapeutic regimens, and reinfection rate after successful eradication in a tertiary clinic. Korean J Gastroenterol 2003;41: 1-8
  34. Kang MS, Park DI, Yun JW, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;47:30-36
  35. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14:1237-1243
  36. de Boer WA, Drissen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:1993-1997
  37. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-991
  38. Cheon JH, Kim N, Lee DH, et al. Trial of moxifloxacincontaining triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Korean J Gastroenterol 2005;45:111-117
  39. Matsuzaki K, Koyama H, Chiba A, et al. In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates. Jpn J Antibiot 1999;52:571-584
  40. Krinchhoff RM, Laufen H, Schake G, Kirchhoff G, Gallo E. Determination of azitrhomycin in gastric biopsy samples. Int J Clin Pharmacol Ther 1999;37:361-364
  41. Blandizzi C, Malizia T, Cherardi G, et al. Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J Antimicrob Chemother 1998;42:75-82
  42. Trautmann M, Riediger C, Moriche A, Vogt K, Bohr U, Glasbrenner B. Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Helicobacter 1999;4: 113-120
  43. Malizia T, Tejada M, Marchetti F, et al. Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. J Antimicrob Chemother 1998;41(suppl B):29S-35S
  44. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacinbased triple therapy as second-line treatments for Helicobacter pylori infection. Helicobacter 2006;11:46-51
  45. Gisbert JP, Calvet X, Bujanda L, et al. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-94
  46. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue' therapy. Aliment Pharmacol Ther 2001;15:143
  47. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17:553-560